Search

CN-118697819-B - Pharmaceutical composition for treating sepsis and preparation method and application thereof

CN118697819BCN 118697819 BCN118697819 BCN 118697819BCN-118697819-B

Abstract

The invention relates to the technical field of pharmaceutical compositions, in particular to a pharmaceutical composition for treating sepsis and a preparation method thereof. The pharmaceutical composition for treating sepsis is prepared from, by mass, 20-26 parts of common andrographis herb, 18-24 parts of weeping forsythiae capsule, 17-21 parts of common anemarrhena rhizome, 15-19 parts of cowherb seed, 14-18 parts of ox flower, 12-16 parts of figwort root, 10-14 parts of coptis root, 7-11 parts of szechwan chinaberry fruit, 5-9 parts of peach leaf and 3-7 parts of longhairy antenoron herb. The formula of the invention can reduce inflammatory reaction of sepsis, lighten apoptosis of intestinal mucosa epithelial cells of the sepsis, promote cell survival and inhibit organ injury after the sepsis.

Inventors

  • TIAN ZHENGYUN
  • LI GUOCHEN
  • HAO HAO
  • FAN KAILIANG
  • KONG LI
  • DUAN LIYUN

Assignees

  • 山东中医药大学附属医院

Dates

Publication Date
20260505
Application Date
20240606

Claims (10)

  1. 1. The pharmaceutical composition for treating sepsis is characterized by being prepared from, by mass, 20-26 parts of common andrographis herb, 18-24 parts of weeping forsythiae capsule, 17-21 parts of common anemarrhena rhizome, 15-19 parts of cowherb seed, 14-18 parts of ox flower, 12-16 parts of figwort root, 10-14 parts of coptis chinensis, 7-11 parts of szechwan chinaberry fruit, 5-9 parts of peach leaf and 3-7 parts of longhairy antenoron herb.
  2. 2. A method of preparing a pharmaceutical composition for the treatment of sepsis according to claim 1, characterized by the steps of: (1) Mixing herba Andrographitis, fructus forsythiae, rhizoma anemarrhenae, semen Vaccariae, flos Bubali, radix scrophulariae, coptidis rhizoma, fructus Toosendan, folium Persicae and herba Tripterygii Wilfordii to obtain material 1; (2) Mixing the material 1, mixed enzyme and water for enzymolysis, filtering after enzyme deactivation, centrifuging, and taking a supernatant; (3) Concentrating the supernatant, and drying to obtain the pharmaceutical composition for treating sepsis.
  3. 3. The preparation method of claim 2, wherein the mass ratio of the material 1, the mixed enzyme and the water in the step (2) is 8-12:0.3-0.5:100.
  4. 4. The preparation method of the enzyme composition according to claim 3, wherein the mixed enzyme is cellulase, protease and alpha-amylase, and the mass ratio of the cellulase to the protease to the alpha-amylase is 12-16:5-9:7-11.
  5. 5. The preparation method of claim 4, wherein the cellulase, the protease and the alpha-amylase have enzyme activities of 3200-3800U/g.
  6. 6. The preparation method of claim 2, wherein the enzymolysis in the step (2) is performed at a temperature of 42-48 ℃ for 2.5-3.5 hours.
  7. 7. The method according to claim 2, wherein the rotational speed of the centrifugation in the step (2) is 2200 to 2800rpm for 5 to 9 minutes.
  8. 8. The method according to claim 2, wherein the supernatant in step (3) is concentrated to 1/5 to 1/3 of the original volume.
  9. 9. The preparation method of the water-based paint, according to claim 2, wherein the drying in the step (3) is spray drying, the air inlet temperature of the spray drying is 128-136 ℃, and the air outlet temperature of the spray drying is 67-73 ℃.
  10. 10. Use of a pharmaceutical composition according to claim 1 or a pharmaceutical composition prepared by a method according to any one of claims 2 to 9 in the preparation of a medicament for the treatment of sepsis.

Description

Pharmaceutical composition for treating sepsis and preparation method and application thereof Technical Field The invention relates to the technical field of pharmaceutical compositions, in particular to a pharmaceutical composition for treating sepsis, and a preparation method and application thereof. Background Sepsis is a systemic inflammatory response of the body to infection, is a common complication of severe infection, severe trauma, post-major surgery, severe acute pancreatitis, shock, and the like, and further development can lead to infectious shock and multiple organ dysfunction syndrome. Although the anti-infection treatment, surgical technique, critical illness monitoring and treatment technique are greatly progressed, the death rate of sepsis is still as high as 29% -38%, and how to improve the prognosis of sepsis patients is a significant problem and difficult problem in the field of acute critical illness. Sepsis is a disorder of the body's response to infection resulting in life threatening organ dysfunction. Starting from the pathogenesis of sepsis and the molecular mechanisms of its resulting organ failure, the development of related therapies aimed at preventing or limiting the progression of fatal organ failure is therefore a currently urgent therapeutic strategy. Yao teaches that immune modulation therapy against sepsis, in which immune depletion occurs in the late stage of sepsis, is of great importance for prognosis of sepsis patients and for severe sepsis therapy, by modulating the innate and acquired immune systems so as to prevent "secondary infections". However, since early sepsis injury is a multiple organ injury caused by excessive release of inflammatory factor storm, intervention with early excessive inflammatory reaction as a window is also one of sepsis prevention and treatment means. In recent years, cell death is considered to be one of important pathological changes of sepsis, while previous researches mainly focus on cell necrosis and apoptosis, and neglect cell autophagy, which is the third death mode of cells. Autophagy, an important component of programmed death, has not been gaining increasing attention until recently. Autophagy is intended to be autophagy, has high species homology, is widely present in eukaryotic cells, and has the effects of degrading false proteins, phagocytizing bacteria, presenting antigens and the like. In sepsis, the release of pro-inflammatory factors can be controlled through autophagy to play a role in protection, so that the autophagy can be used as a research target, and a new prospect for treating sepsis can be developed through regulating autophagy. Studies have demonstrated that in the sepsis model, following LPS stimulation, bacterial infection, autophagy is increased, which can play a role in protecting cells from cell death. Among the numerous target organs damaged by sepsis, the gastrointestinal tract is the most vulnerable target organ when sepsis induces multiple organ dysfunction, and at the same time, gastrointestinal dysfunction plays an important role in the pathogenesis of sepsis, and is often considered as an initiating factor of sepsis multiple organ failure and is a starting organ of sepsis. The key to the treatment of gastrointestinal dysfunction is to maintain the intestinal mucosal barrier, reestablish the continuity of the intestinal tract, and regulate homeostasis, circulation and oxygen supply. Sepsis most often involves the intestinal tract, causing edema in the intestinal mucosa, rupture of epithelial cell membranes and intercellular junctions, necrosis of cells, shedding of epithelium from the top of villi, even complete shedding of mucosa to form ulcers, increased intestinal permeability, impaired mechanical barrier function, translocation of bacteria and endotoxins, exacerbation of SIRS and runaway of the control, and induction of MODS endangering the life of the patient. Therefore, the mechanical barrier formed by the intestinal mucosa epithelial cells is a first defense line for blocking the invasion of microorganisms and is also an anatomical basis for smoothly realizing the other barrier functions. The pathogenesis of intestinal mucosa epithelial cell injury is closely related to endotoxemia, and the endotoxemia can cause the intestinal mucosa epithelial cell to be damaged, the barrier function to be destroyed and a large number of bacteria to shift through hypoxia, inflammatory mediator release and free radical increase, and finally cause multiple organ failure and even death. Therefore, how to protect intestinal mucosal epithelial cells and barrier function, alleviate gastrointestinal dysfunction is a key problem in improving sepsis prognosis, and reducing sensitivity of intestinal mucosal epithelial cells to bacterial endotoxin by modulating inflammatory response is an important strategy. Disclosure of Invention The invention aims to provide a pharmaceutical composition for treating sepsis and a prepar